Medtronic plc (MDT)

NYSE: MDT · USD

$94.7

+0.74 (+0.8%)· Recorded snapshot

Engelse bronNL

Engelse bron wordt weergegeven terwijl we vertalen

Dit rapport is nog niet vertaald. Vernieuw over een paar minuten zodra de vertaalwachtrij is bijgewerkt.

StockMarketAgent Research · Analyzed 2026-05-12

Our latest published analysis: MDT rated Buy

Medtronic plc's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$95.9 / share

Potential value

$114 / share

Upside to FV

+24.8%

from $94.7

Moat

9/10

Wide

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$98.6B
Revenue (ttm)	37.5B
Net income (ttm)	5.2B
EPS (ttm)	$4.06
Shares out	1.2B
P/E (trailing)	23.3x
P/E (forward)	12.7x
Dividend	$2.88 (3.03%)
Volume	7,466,922
Beta	0.57

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 37.5B
Net income (ttm): 5.2B
EPS (ttm): $4.06
P/E (trailing): 23.3x
P/E (forward): 12.7x
Market cap: $98.6B

Item	P1	P2	P3	P4	Trend
Period	2022-04-30	2023-04-30	2024-04-30	2025-04-30	Trend
Revenue	$31.69B	$31.23B	$32.36B	$33.54B	+1.9%
Gross profit	$21.54B	$20.51B	$21.15B	$21.91B	+0.6%
Operating income	$6.07B	$6.00B	$5.56B	$6.36B	+1.6%
Net income	$5.04B	$3.76B	$3.68B	$4.66B	-2.6%
EPS (diluted)	$3.73	$2.82	$2.76	$3.61	-1.1%
EBITDA	$8.78B	$8.70B	$8.20B	$9.22B	+1.6%
R&D	$2.75B	$2.70B	$2.74B	$2.73B	-0.2%
SG&A	$10.29B	$10.42B	$10.74B	$10.85B	+1.8%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	Verkopen
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	Verminderen
ACN	Accenture plc	144.3B	18.0x	2.0x	27.9%	+8.0%	+0.4%	Aanhouden
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	Verminderen
ALNY	Alnylam Pharmaceuticals, Inc.	31.1B	41.4x	6.4x	96.6%	+47.5%	-52.1%	Sterk kopen
AMGN	Amgen Inc.	244.2B	28.1x	6.4x	19.8%	+8.4%	+58.6%	Kopen

Base and Bull scenarios

Bull20%

Price target

$113.75

+48.1% from spot

Successful launch and rapid adoption of new therapies reignite mid-single-digit top-line growth, driving operating leverage and margin expansion.

Multiple re-rates above 14x.
Revenue growth accelerates past 5%.

Base60%

Price target

$95.89

+24.8% from spot

Medtronic maintains stable free cash flow and dividend payouts despite sluggish near-term execution, supported by entrenched market share.

Terminal multiple capped at 14x.
Operating margins held flat at 19.5%.

Sensitivity: Ke × terminal growth

Ke ↓ / g →	1.5%	2.0%	2.5%	3.0%	3.5%
4.6%	$119	$142	$158	$158	$158
5.6%	$90.4	$103	$119	$142	$158
6.6%	$72.7	$80.6	$90.4	$103	$119
7.6%	$60.9	$66.3	$72.7	$80.6	$90.4
8.6%	$52.3	$56.3	$60.9	$66.3	$72.7

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E12.7

P25 n/aP50 n/aP75 n/a

Trailing P/E21.5

P25 n/aP50 n/aP75 n/a

ROE10.6

P25 n/aP50 n/aP75 n/a

ROIC8.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All MDT indicators

Market & fundamental data

Available fields

291

Groups with data

Currency

USD

Showing 291 of 291 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001613103
Company name	Medtronic plc
Country	Ireland
Country code	US
CUSIP number	G5960L103
Earnings date	2026-11-17
Earnings time	bmo
Employees	95,000
Employees change	0
Employees growth	0%
Enterprise value	$135.1B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-07-31
First seen	2026-05-09
Fiscal year end	April
Founded	1949
In index	SP500
Industry	Medical Devices
Is primary listing	Yes
Is SPAC	No
ISIN number	IE00BTN1Y115
Last 10-K release date	2026-06-18
Last earnings date	2026-09-01
Last refreshed	2026-10-28
Last stock split date	1999-09-27
Last stock split type	Forward
Market cap	$115.9B
Market cap category	Large-Cap
Next earnings date	2026-11-17
Options	Yes
Price	$94.69
Price currency	USD
Sector	Healthcare
SIC code	3845
Stock price date	2026-10-28
Symbol	MDT
Website	https://www.medtronic.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	16.55x
Average P/E ratio (10Y)	30.46x
Average P/E ratio (3Y)	25.32x
Average P/E ratio (5Y)	26.8x
Earnings yield	4.29%
EV/Earnings	25.95x
EV/EBIT	17.99x
EV/EBITDA	13.04x
EV/FCF	22.14x
EV/Sales	3.62x
FCF / EV yield	4.52%
FCF yield	5.26%
Forward EV/Sales	3.47x
Forward P/E	15.83x
Forward P/S	2.98x
Graham number	59.86975
Graham upside	-37.14%
Industry forward P/E	19.74x
Industry P/E	39.16x
Lynch fair value	$24.95
Lynch upside	-73.8%
P/(FCF - SBC) ratio	20.69x
P/(OCF - SBC) ratio	15.46x
P/B ratio	2.39x
P/E ratio	23.33x
P/FCF ratio	19.01x
P/OCF ratio	14.51x
P/S ratio	3.11x
PEG ratio	3.18x
Price/EBITDA ratio	11.2x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	20.1%
EBITDA margin	27.72%
Effective tax rate	20.19%
FCF margin	16.33%
Gross margin	65.27%
Operating margin	20.1%
Pretax margin	17.59%
Profit margin	13.93%
Profit per employee	$55,063
Profitable quarters	34
Profitable years	34
Revenue per employee	$395,179
ROA	5.12%
ROA (5Y)	4.49%
ROCE	9.26%
ROE	10.65%
ROE (5Y)	8.71%
ROIC	8.59%
ROIC (5Y)	7.72%
SBC / revenue	1.32%
Tax / revenue	3.55%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	12.12%
EPS growth (Q)	40.74%
EPS growth (QoQ)	17.56%
EPS growth 10Y	4.68%
EPS growth 3Y	14.42%
EPS growth 5Y	7.27%
EPS growth quarters	2
EPS growth years	2
FCF growth	15.63%
FCF growth (Q)	120.89%
FCF growth (QoQ)	-38.13%
FCF growth 3Y	11.33%
FCF growth 5Y	0.93%
Gross profit growth	9.58%
Gross profit growth (Q)	13.5%
Gross profit growth 3Y	5.58%
Gross profit growth 5Y	2.93%
Net income growth	12.25%
Net income growth (Q)	41.35%
Net income growth (QoQ)	18.17%
Net income growth 3Y	13.06%
Net income growth 5Y	6.15%
Net income growth quarters	2
Net income growth years	2
OCF growth	12.44%
OCF growth (Q)	64.8%
OCF growth (QoQ)	-30.31%
OCF growth 10Y	3.05%
OCF growth 3Y	11.28%
OCF growth 5Y	2.07%
Operating income growth	15.37%
Operating income growth (Q)	17.36%
Operating income growth 3Y	7.78%
Operating income growth 5Y	3.02%
Revenue growth	9.77%
Revenue growth (Q)	13.73%
Revenue growth (QoQ)	-0.52%
Revenue growth 10Y	2.71%
Revenue growth 3Y	5.96%
Revenue growth 5Y	3.51%
Revenue growth quarters	14
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1.9B
Depreciation and amortization	$2.9B
EBIT	$7.5B
EBITDA	$10.4B
EPS	$4.06
FCF per share	$5.01
Financing cash flow	$-3.7B
Free cash flow	$6.1B
Free cash flow minus SBC	$5.6B
Gross profit	$24.5B
Income taxes	$1.3B
Investing cash flow	$-3.8B
Net borrowing	$151M
Net cash flow	$418M
Net income	$5.2B
Operating cash flow minus SBC	$7.5B
Operating income	$7.5B
Revenue	$37.5B
Stock-based compensation	$496M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.98
Book value per share	$39.24
Debt / EBITDA	2.63
Debt / equity	0.55
Debt / FCF	4.59
Goodwill	$43.2B
Interest coverage	10.41
Long-term assets	$68.9B
Long-term liabilities	$30.7B
Net cash (debt)	$-19.2B
Net cash / market cap	-16.44%
Net debt / EBITDA	1.84
Net debt / equity	0.38
Net debt / FCF	3.13
Piotroski F-Score	7
Property, plant and equipment	$7.5B
Shareholders' equity	$50.9B
Tangible book value	$-3.2B
Tangible book value per share	$-2.49
Total assets	$93.3B
Total cash	$8.8B
Total debt	$28.2B
Total liabilities	$42.5B
WACC	6.34%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.41
Current assets	$24.4B
Current liabilities	$11.8B
Current ratio	2.07
Inventory turnover	2.15
Net working capital	$6.3B
Quick ratio	1.29
Working capital	$12.6B
Working capital turnover	3.09

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0%
Dividend growth	1.42%
Dividend growth (10Y)	5.85%
Dividend growth (3Y)	1.44%
Dividend growth (5Y)	3.4%
Dividend growth years	50
Dividend payment date	2026-10-16
Dividend payment years	50
Dividend payout frequency	Quarterly
Dividend per share	$2.88
Dividend yield	3.03%
Ex-dividend date	2026-09-25
FCF payout ratio	57.49%
Last dividend	$0.72
Payout ratio	70.94%
Shareholder yield	3.02%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	17.31%
10Y return CAGR	4.38%
10Y total return	53.57%
150-day SMA	$85.50
15Y price change	171.77%
15Y return CAGR	9.59%
15Y total return	295.19%
1D price change	0.79%
1M price change	7.37%
1M total return	7.37%
1W price change	0.58%
1W total return	0.58%
1Y price change	1.11%
1Y return CAGR	4.46%
1Y total return	4.46%
20-day SMA	$91.77
200-day SMA	$88.17
20Y price change	95.55%
20Y return CAGR	5.86%
20Y total return	212.24%
3M price change	13.01%
3M total return	13.93%
3Y price change	37.08%
3Y return CAGR	14.78%
3Y total return	51.23%
50-day SMA	$91.57
50-day SMA vs 200-day SMA	50over200
52-week high	$106.33
52-week high date	2025-11-26
52-week low	$73.31
52-week low date	2026-06-02
5Y price change	-22.31%
5Y return CAGR	-1.83%
5Y total return	-8.83%
6M price change	14.78%
6M total return	16.77%
All-time high	$135.89
All-time high date	2021-09-09
All-time low	$0.13
All-time low date	1977-12-01
Average true range (ATR)	$2.28
Average volume	30.6M
Beta (1Y)	-0.3
Beta (2Y)	0.3
Beta (5Y)	0.57
Change from 52-week high	-10.95%
Change from 52-week low	29.16%
Change from all-time high	-29.96%
Change from all-time low	73,167.9%
Change from open	1.62%
Day's gap	-0.82%
Dollar volume	$707M
High price	$95.68
Low price	$93.18
Monthly RSI	54.28
Open price	$93.18
Position in 52-week range	60.4%
Premarket change	-1.19%
Premarket close	$93.95
Premarket price	$92.83
Premarket volume	4.8K
Previous close	$93.95
Price vs 150-day SMA	11.32%
Price vs 20-day SMA	3.71%
Price vs 200-day SMA	7.94%
Price vs 50-day SMA	3.94%
Relative volume	0.24
RSI	58.2
Sharpe ratio	0.14
Sharpe ratio (3Y)	0.5
Sharpe ratio (5Y)	-0.14
Sortino ratio	0.46
Sortino ratio (3Y)	1
Sortino ratio (5Y)	0.05
Volume	7.5M
Weekly RSI	59.32
YTD price change	-0.92%
YTD total return	1.62%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.2B
Float percentage	99.8%
Shares change (QoQ)	-0.24%
Shares change (YoY)	0%
Shares held by insiders	0.04%
Shares held by institutions	91.03%
Shares outstanding	1.2B
Short % of float	3.27%
Short % of shares	3.27%
Short ratio	3.4 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	129

Deeper analysis on MDT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this MDT report

What is the latest published MDT stock rating?

Medtronic plc is shown with Buy in the latest published report, analyzed 2026-05-12. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full MDT analysis?

The full latest published report, analyzed 2026-05-12, lives at /stocks/MDT/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for MDT?

The latest published report analyzed 2026-05-12 gives MDT a fair value of USD 96 and a potential value of USD 114. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the MDT page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-12). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

BuyMDT · Fair value $95.9+24.8%

Read full analysis →

Medtronic plc (MDT)

Our latest published analysis: MDT rated Buy

Price

Financial snapshot

Fair-value bridge

Latest news · MDT

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All MDT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on MDT

Frequently asked questions

Ratinggeschiedenis

Category	Score	Reading
Valuation	7.5
Management	7.3
Balance Sheet	7.5
Profitability	5.5
Revenue Growth	6.0
Risk Assessment	8.0
Competitive Moat	9.0
Earnings Quality	6.0
Capital Efficiency	5.5